Article Figures & Data
Figures
- FIG 1
Box (median and 25th to 75th percentiles) and whisker (5th and 95th percentiles) plots of voriconazole trough concentrations for patients with no to mild inflammation (n = 48), moderate inflammation (n = 60), and severe inflammation (n = 20). The filled circles represent outliers. The median (interquartile range [IQR]) voriconazole dose (in mg/kg of body weight) for each group is displayed above each box-and-whisker plot. The dotted lines represent the therapeutic window of voriconazole trough concentrations.
- FIG 2
Voriconazole trough concentrations (solid curve) and CRP concentrations (dashed curve) of a 46-year-old male patient with cystic fibrosis who was admitted to the intensive care unit with respiratory insufficiency and was treated with voriconazole after Aspergillus fumigatus was isolated from his respiratory secretions. On day 24, the patient received a bilateral lung transplant. The dotted lines represent the therapeutic window of voriconazole.
Tables
- TABLE 1
Patient characteristicsa
Characteristic No. (%) of patients or median (IQR) Demographic Gender (female) 59 (46) Age (yr) 55 (42–62) Weight (kg) 75 (61–85) Height (m) 1.75 (1.67–1.81) BMIb (kg/m2) 24.2 (21.6–26.6) Underlying disease Hematologic malignancy 67 (52) Solid organ transplant 34 (27) Otherc 27 (21) Voriconazole treatment Twice-daily dose (mg/kg) 3.3 (2.6–3.9) Intravenous administration 64 (50) Laboratory parameter Voriconazole (mg/liter) 2.7 (1.3–4.8) CRP (mg/liter) 71 (15–152) Alkaline phosphatase (U/liter) 114 (71–192) ALT (U/liter) 36 (17–69) AST (U/liter) 31 (19–61) γ-Glutamyl transferase (U/liter) 105 (55–232) Total bilirubin (μmol/liter) 9 (6–16) Coadministered medication (Es)omeprazole 81 (63)
